Hu Bcl-2 (pS70) PE-CF594 N46-467 50Tst
货号：
562679 基本售价：
3920.0 元 规格：
50Tst
产品信息
概述| 货号 | 562679 |
| 描述 | The N46-467 monoclonal antibody specifically binds to Bcl-2 (pS70), ie, the Bcl-2 protein phosphorylated at the Ser70 site. Bcl-2 is a ~ 26 kDa intracellular, integral membrane protein found primarily in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membrane. Bcl-2 is encoded by the BCL2 (B-cell CLL/lymphoma 2) gene and is also known as Apoptosis regulator Bcl-2. Members of the Bcl-2 family play a major role in regulating the response of cells to apoptotic signals. Bcl-2 is one of the anti-apoptotic members of the Bcl-2 family. Bcl-2 knockout mice showed pronounced lymphoid apoptosis and other apoptosis related lesions later in life. Bcl-2 is a proto-oncogene because it blocks apoptosis and provides a selective survival advantage in many cell types and thus contributes to tumorigenesis. It has been implicated in several types of cancers, such as breast, prostate, and melanoma . Bcl-2 contains multiple phosphorylation sites including Thr56, Ser70, Thr74 and Ser87. Phosphorylation of Bcl-2 Ser70 has been shown to be a mitotic marker. Phosphorylation at this site regulates Bcl-2s anti-apoptotic activity and has recently been implicated in promoting autophagy. Several studies have shown that Bcl-2 phosphorylation is caused by c-Jun N-terminal kinase (JNK). |
| 别名 | BCL2; Apoptosis regulator Bcl-2; B-cell CLL/lymphoma 2; PPP1R50 |
| 同种亚型 | Mouse IgG1 |
| 反应种属 | Human (QC Testing) Mouse (Tested in Development) |
性能| 供应商 | BD Pharmingen |
| 免疫原 | Phosphorylated Peptide |
| 标记 | PE-CF594 |
| 存放说明 | Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.The antibody was conjugated with BD Horizon™ PE-CF594 under optimum conditions, and unconjugated antibody and free PE-CF594 were removed.
|
| 存储溶液 | Aqueous buffered solution containing BSA and ≤0.09% sodium azide. |
